Cytosorbents Corporation (CTSO) News
Filter CTSO News Items
CTSO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CTSO News Highlights
- CTSO's 30 day story count now stands at 4.
- Over the past 15 days, the trend for CTSO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC, NOTE and SAFE are the most mentioned tickers in articles about CTSO.
Latest CTSO News From Around the Web
Below are the latest news stories about CYTOSORBENTS CORP that investors may wish to consider to help them evaluate CTSO as an investment opportunity.
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board RecommendationPRINCETON, N.J., Dec. 28, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announces an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board (“DSMB”) analysis for the pivotal U.S. and Canadian STAR-T (Safe and |
Insider Spends US$100k Buying More Shares In CytosorbentsInvestors who take an interest in Cytosorbents Corporation ( NASDAQ:CTSO ) should definitely note that the CEO... |
Insider Buying: CEO Phillip Chan Acquires 75,188 Shares of CytoSorbents Corp (CTSO)Recent insider trading activity has caught the attention of investors as Phillip Chan, CEO of CytoSorbents Corp, made a significant purchase of company shares. |
CytoSorbents Announces Closing of $10.3 Million Registered Direct OfferingCompany insiders participated in the transaction with $435,000 of investmentPRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announces the closing of its previously announced registered direct offering for the sale by the Company directly to investors of an aggregate of |
CTSO: CytoSorbents reports 3rd quarter 2023 financial and operating results which showed strong product revenue growth and an improved cost structure.By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents (NASDAQ:CTSO) reported 3rd quarter 2023 results on November 9th which showed strong product revenue growth. 3rd quarter product revenues increased 20% to $7.8 million and grant income decreased 35.9%. The increase in the Euro to U.S. dollar exchange rate positively impacted product sales by approximately $508,000. The |
Q3 2023 Cytosorbents Corp Earnings CallQ3 2023 Cytosorbents Corp Earnings Call |
Cytosorbents Corporation (NASDAQ:CTSO) Q3 2023 Earnings Call TranscriptCytosorbents Corporation (NASDAQ:CTSO) Q3 2023 Earnings Call Transcript November 9, 2023 Cytosorbents Corporation misses on earnings expectations. Reported EPS is $-0.20718 EPS, expectations were $-0.12. Operator: Good afternoon, and welcome to CytoSorbents third quarter 2023 financial and operating results conference call. [Operator Instructions]. Please be advised that the call will be recorded at the company’s […] |
CytoSorbents Reports Third Quarter 2023 Financial and Operational ResultsQ3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data analysis completion expected before year-end.PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorptio |
CytoSorbents to Report Third Quarter 2023 Operating and Financial ResultsPRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2023 operating and financial results after the market close on Thursday, November 9th, 2023. CytoSorbents’ management will host a live presentation webcast and a question and answer session at 4:30PM EDT the same day. Webcast Details:Date: Thursday, No |
CytoSorbents to Present at the 8th Annual Dawson James ConferencePRINCETON, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Dawson James Small Cap Growth conference at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, FL on Thursday, October 12th, 2023. Company management will also meet in-person with investors in |